Related search

Metastatic Castration-Resistant Prostate Cancer: Critical Review of Enzalutamide

Clinical Medicine Insights: Oncology
Oncology
2013English

Enzalutamide and Abiraterone in the Treatment of Metastatic Castration-Resistant Prostate Cancer After Chemotherapy

Klinicka Onkologie
Oncology
2016English

Radiotherapy in Metastatic Castration Resistant Prostate Cancer Patients With Oligo-Progression During Abiraterone-Enzalutamide Treatment: A Mono-Institutional Experience

Radiation Oncology
Nuclear MedicineRadiologyImagingOncology
2019English

Budget Impact Analysis of Enzalutamide for Treatment of Metastatic Castration-Resistant Prostate Cancer From a u.s. Payer Perspective

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2015English

Mp52-01 Combination of Indomethacin and Enzalutamide to Treat Castration-Resistant Prostate Cancer

Journal of Urology
Urology
2018English

Pharmacoeconomic Evaluation of Enzalutamide, Abiraterone and Cabazitaxel for the Treatment of Post-Chemotherapy Patients With Metastatic Castration-Resistant Prostate Cancer

Medical Technologies. Assessment and Choice (Медицинские технологии. Оценка и выбор)
2018English

The Treatment Patterns of Castration Resistant Prostate Cancer in Japan

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2015English

A Multicenter Phase I/Ii Study of Enzalutamide in Japanese Patients With Castration-Resistant Prostate Cancer

International Journal of Clinical Oncology
MedicineSurgeryOncologyHematology
2016English

Pcn37 - Matching-Adjusted Indirect Comparison of the Efficacy of Apalutamide and Enzalutamide in the Treatment of Non-Metastatic Castration-Resistant Prostate Cancer

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2025 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy